StockData
Amgen Inc logo

Amgen Inc (AMGN) stock

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$457.93−4.39 (-0.95%)

Close on Nov 17, 2026Market cap $247.57BP/E 26.5Yield 2.11%

Amgen price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Amgen's price to sales ratio was 6.6× on Nov 11, 2026, against 5.2× a year earlier. Over the last 5 years it ranged from 4.3× to 6.6×, with a median of 5.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20266.6×+1.7
2025Dec 31, 20254.9×+0.6
2024Dec 31, 20244.3×−1.4
2023Dec 29, 20235.7×+0.4
2022Dec 30, 20225.3×+0.3
2021Dec 31, 20215.1×−0.7
2020Dec 31, 20205.7×−0.4
2019Dec 31, 20196.2×+0.7
2018Dec 31, 20185.5×−0.1
2017Dec 29, 20175.6×+0.5
2016Dec 30, 20165.1×−0.8
2015Dec 31, 20155.9×−0.5
2014Dec 31, 20146.4×+1.4
2013Dec 31, 20135.0×+0.7
2012Dec 31, 20124.2×+0.2
2011Dec 30, 20114.1×+0.5
2010Dec 31, 20103.6×−0.4
2009Dec 31, 20094.0×–

More Amgen figures

See a number that looks wrong?